Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735829 | 0.99 | NPC1 (0.34) | NPC1CYP1A2CYP2C9HPGDCYP2C19 | |
| Tetrabuthylammonium SCHEMBL20508724 | 0.93 | NPC1 (0.31) | NPC1CYP1A2CYP2C9HPGDCYP2C19 | |
| Tetramethylammonium Ion SCHEMBL1263432 | 0.87 | NPC1 (0.31) | NPC1CYP1A2CYP2C9HPGDCYP2C19 | |
| Tetrabuthylammonium SCHEMBL810740 | 0.84 | — | — | |
| SCHEMBL4640598 | 0.77 | SCN5A (0.39) | EPHX2 | |
| SCHEMBL25409960 | 0.75 | LMNA (0.39) | SMN1; SMN2EPHX2 | |
| SCHEMBL8016538 | 0.74 | FAAH (0.35) | HPGDSMN1; SMN2 | |
| SCHEMBL25406912 | 0.74 | CYP1A2 (0.36) | CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL8019381 | 0.74 | MEN1 (0.36) | — | |
| SCHEMBL4606555 | 0.72 | SLC7A5 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242360-B2 | Process for the manufacturing of triaryl-organo borates | COVESTRO DEUTSCHLAND AG (DE) | 2022-02-08 | — | — | US | disclosed |
| US-20200062786-A1 | PROCESS FOR THE MANUFACTURING OF TRIARYL-ORGANO BORATES | COVESTRO DEUTSCHLAND AG (DE) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062786-A1 | PROCESS FOR THE MANUFACTURING OF TRIARYL-ORGANO BORATES | PARG, BRS3, BLVRB | NPC1 3844/4885CYP1A2 154/4885CYP2C9 672/4885 |
| US-11242360-B2 | Process for the manufacturing of triaryl-organo borates | PARG, BRS3, BLVRB | NPC1 3844/4885CYP1A2 154/4885CYP2C9 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.